Literature DB >> 21180612

Review of the safety and efficacy of ustekinumab.

Ellen J Scherl1, Sheila Kumar, Ryan U Warren.   

Abstract

Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

Entities:  

Keywords:  Crohn’s disease; anti-interleukin 12/23; antitumor necrosis factor; infliximab; primary nonresponder; secondary nonresponder; suboptimal infliximab response; ustekinumab

Year:  2010        PMID： 21180612      PMCID： PMC3002587          DOI： 10.1177/1756283X10374216

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  27 in total

1.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors:  Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

3.  The IL-23/IL-17 axis in inflammation.

Authors:  Yoichiro Iwakura; Harumichi Ishigame
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

5.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.

Authors:  Michele Cargill; Steven J Schrodi; Monica Chang; Veronica E Garcia; Rhonda Brandon; Kristina P Callis; Nori Matsunami; Kristin G Ardlie; Daniel Civello; Joseph J Catanese; Diane U Leong; Jackie M Panko; Linda B McAllister; Christopher B Hansen; Jason Papenfuss; Stephen M Prescott; Thomas J White; Mark F Leppert; Gerald G Krueger; Ann B Begovich
Journal:  Am J Hum Genet       Date:  2006-12-21       Impact factor: 11.025

8.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

9.  Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease.

Authors:  Gary P Toedter; Marion Blank; Yinghua Lang; Dion Chen; William J Sandborn; Willem J S de Villiers
Journal:  Am J Gastroenterol       Date:  2009-08-11       Impact factor: 10.864

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682
View more
  11 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Ustekinumab in Crohn's disease: evidence to date and place in therapy.

Authors:  Tal Engel; Uri Kopylov
Journal:  Ther Adv Chronic Dis       Date:  2016-07-06       Impact factor: 5.091

3.  Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis.

Authors:  Akiko Kurishima; Muneo Inaba; Yutaku Sakaguchi; Toshiro Fukui; Kazushige Uchida; Akiyoshi Nishio; Shosaku Nomura; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2013-09-29       Impact factor: 7.527

Review 4.  Ustekinumab for the treatment of Crohn's disease: can it find its niche?

Authors:  Ebby G Simon; Subrata Ghosh; Marietta Iacucci; Gordon W Moran
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 5.  New and Emerging Therapies for Alopecia Areata.

Authors:  Aunna Pourang; Natasha Atanaskova Mesinkovska
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

6.  Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?

Authors:  Reinhart Speeckaert; Jo Lambert; Luis Puig; Marijn Speeckaert; Hilde Lapeere; Sofie De Schepper; Nanja van Geel
Journal:  Drugs R D       Date:  2021-06-09

Review 7.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

8.  Late reaction to ustekinumab infusion.

Authors:  Marina Resener Morais; Luana Pizarro Meneghello; Carina Flores de Oliveira; André Vicente Esteves Carvalho
Journal:  Dermatol Reports       Date:  2013-09-09

9.  Ustekinumab for the treatment of refractory pediatric Crohn's disease: a single-center experience.

Authors:  Alexandra Cohen; Najma Ahmed; Ana Sant'Anna
Journal:  Intest Res       Date:  2020-04-22

10.  Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement.

Authors:  Eric Toussirot; Fabrice Michel; Matthieu Béreau; Delphine Binda
Journal:  Patient Prefer Adherence       Date:  2013-04-26       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.